Human Complement C5 ELISA Kit (ab125963)
- Datasheet
- References (5)
- Protocols
Overview
-
Product name
Human Complement C5 ELISA Kit
See all C5 kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall 4.1% Inter-assay Sample n Mean SD CV% Overall 9.7% -
Sample type
Cell culture supernatant, Saliva, Milk, Serum, Plasma, Cerebral Spinal Fluid -
Assay type
Sandwich (quantitative) -
Sensitivity
0.1 ng/ml -
Range
0.313 ng/ml - 20 ng/ml -
Recovery
101 %
-
Assay time
4h 00m -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Human Complement C5 ELISA kit (Enzyme-Linked Immunosorbent Assay) is designed for the quantitative measurement of C5 in human plasma, serum, saliva, milk, CSF and cell culture supernatants.
A Complement C5 specific antibody has been precoated onto 96-well plates and blocked. Standards or test samples are added to the wells and subsequently a Complement C5 specific biotinylated detection antibody is added and then followed by washing with wash buffer. Streptavidin-Peroxidase Conjugate is added and unbound conjugates are washed away with wash buffer. TMB is then used to visualize Streptavidin-Peroxidase enzymatic reaction. TMB is catalyzed by Streptavidin-Peroxidase to produce a blue color product that changes into yellow after adding acidic stop solution. The density of yellow coloration is directly proportional to the amount of Complement C5 captured in plate.
The entire kit may be stored at -20°C for long term storage before reconstitution - Avoid repeated freeze-thaw cycles.
-
Platform
Microplate
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 1 x 96 tests 100X Streptavidin-Peroxidase Conjugate 1 x 80µl 10X Diluent N Concentrate 1 x 30ml 20X Wash Buffer Concentrate 2 x 30ml 50X Biotinylated Human Complement C5 Antibody 1 x 120µl Chromogen Substrate 1 x 8ml Complement C5 Microplate (12 x 8 well strips) 1 unit Complement C5 Standard 1 vial Sealing Tapes 3 units Stop Solution 1 x 12ml -
Research areas
-
Function
Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.
Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. C5a also stimulates the locomotion of polymorphonuclear leukocytes (chemokinesis) and direct their migration toward sites of inflammation (chemotaxis). -
Involvement in disease
Defects in C5 are the cause of complement component 5 deficiency (C5D) [MIM:609536]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis.
Note=An association study of C5 haplotypes and genotypes in individuals with chronic hepatitis C virus infection shows that individuals homozygous for the C5_1 haplotype have a significantly higher stage of liver fibrosis than individuals carrying at least 1 other allele (PubMed:15995705). -
Sequence similarities
Contains 1 anaphylatoxin-like domain.
Contains 1 NTR domain. -
Cellular localization
Secreted. - Information by UniProt
-
Alternative names
- Anaphylatoxin C5a analog
- C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4
- C5
see all -
Database links
- Entrez Gene: 727 Human
- Omim: 120900 Human
- SwissProt: P01031 Human
- Unigene: 494997 Human
Images
-
Sandwich ELISA - Complement C5 Human ELISA Kit (ab125963)Complement 5 measured in biological fluids and cell culture medium with background signal subtracted (duplicates +/- SD). -
Typical Stand CurveRepresentative Standard Curve using ab125963
Protocols
References
This product has been referenced in:
- Meng X et al. DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma. EBioMedicine 41:185-199 (2019). Read more (PubMed: 30773478) »
- Kusner LL et al. Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Mol Ther Methods Clin Dev 13:484-492 (2019). Read more (PubMed: 31193726) »
